腫瘍に活性化されたナノコンプレックスは,がんとマクロファージの代謝を逆方向に再プログラムし,免疫抑制を克服します.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。この研究では,硫化水素 (H2S) を取り除き,がん細胞と腫瘍に関連するマクロファージの代謝を再プログラムし,抗腫瘍免疫を強化し,腫瘍の成長を抑制する酸活性化ナノコンプレックスを導入した.
科学分野
- 生物医学工学
- 癌 研究
- 免疫学
背景
- 免疫療法の有効性は,がん細胞と腫瘍関連マクロファージ (TAM) の異なる代謝経路によって駆動される免疫抑制性腫瘍の微環境によって制限されています.
- これらの細胞の同期した代謝再プログラミングは 異なった代謝需要のために困難です
研究 の 目的
- 癌細胞とTAM代謝の同時調節のための新しいナノマテリアルベースの戦略を開発する.
- 抗腫瘍免疫を強化し,腫瘍の進行を抑制するこの戦略の治療の可能性を調査する.
主な方法
- 酸活性化鉄亜鉛ナノ複合体 (FZNC) は,腫瘍の微小環境で尖ったFeOOHナノ粒子に変換するように設計された.
- FZNCは,細胞代謝に影響を与える重要な代謝物である硫化水素 (H2S) を選択的に除去するために使用されました.
- 癌細胞の代謝シフト (OXPHOSからOXPHOSへ) とTAM (OXPHOSからGlycolysisへ) を分析した.
- 免疫性,免疫細胞の浸透,腫瘍の成長,転移をインビトロおよびインビボで評価した.
主要な成果
- FZNCは細胞の吸収を高め,腫瘍の微小環境内で選択的にH2Sを枯渇させました.
- 双方向の代謝再プログラムが達成され,がん細胞は酸化性リン酸化 (OXPHOS) に移行し,TAMは糖分解に移行した.
- この代謝再プログラムにより,腫瘍の免疫性, dendritic 細胞の成熟,M1の極化,および細胞毒性T細胞の浸透が増加しました.
- FZNC治療は,PD- L1阻害と相乗効果を示し,腫瘍の成長と転移を著しく抑制しました.
結論
- 開発されたFZNCは,腫瘍の微小環境内の対極的な代謝プログラムを調整するための材料ベースのアプローチを提供します.
- この戦略は抗腫瘍免疫を効果的に強化し,がん治療の有望な治療法,特に組み合わせた治療法を提供します.
関連する概念動画
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...